Cellular and molecular mechanisms of osteoporosis

Aging Clinical and Experimental Research

Volumn 10, Issue 3, 1998, Pages 182-190

  Manolagas, S C ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Aging; Bone marrow; Cytokines; Glucocorticoids; Postmenopausal osteoporosis

Indexed keywords

BONE REMODELING; CELL DENSITY; HUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; REVIEW;

EID: 0031662703     PISSN: 03949532     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03339652     Document Type: Review

References (69)

1. Parfitt A.M.: Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J. Cell. Biochem. 55: 273-286, 1994.
2. Aubin J.E., Liu F., The osteoblast lineage, in: Bilezikian J.P , Raisz L.G., Rodan G.A. (Eds.), Principles of Bone Biology. Academic Press, San Diego, 1996, pp.51-67.
3. Roodman G.D.: Advances in bone biology: The osteoclast Endocr. Rev. 17: 308-332, 1996.
4. Manolagas S.C., Jilka R.L., Bellido T., O'Brien C.A., Parfitt A.M.: Interleukin-6-type cytokines and their receptors. In: Bilezikian J P., Raisz L G., Rodan G.A. (Eds.), Principles of Bone Biology. Academic Press, San Diego, 1996. pp. 701-713.
5. Yamate T , Mocharla H., Taguchi Y . lgietseme J.U., Manolagas S.C., Abe E.: Osteopontin expression by osteoclast and osteoblast progenitors in the murine bone marrow: demonstration of its requirement for osteoclastogenesis and its increase after ovariectomy. Endocrinology 138: 3047-3055, 1997.
6. Parfitt A.M., Mundy G.R., Roodman G.D., Hughes D.E , Boyce B.F.: A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J. Bone Miner. Res. 11: 150-159, 1996.
7. Hayden J.M., Mohan S., Baylink D.J.: The insulin-like growth factor system and the coupling of formation to resorption. Bone 17 (Suppl.): 93S-98S, 1995.
8. Pfeilschifter J., Mundy G.R,: Modulation of type β transforming growth factor activity in bone cultures by osteotropic hormones. Proc Natl. Acad. Sci. USA 84: 2024-2028, 1987.
9. Suda T., Takahashi N., Martin T.J.: Modulation of osteoclast differentiation. Endocr. Rev. 13: 66-80, 1992.
10. Komori T., Yagi H., Nomura S., Yamaguchi A., Sasaki K., Deguchi K., Shimizu Y., Bronson R.T , Gao Y-H., Inada M., Sato M., Okamoto T , Kitamura Y., Yoshiki S., Kishimoto T.: Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89: 755-764, 1997.
11. Otto F., Thomell A.P., Crompton T., Denzel A., Gilmour K.C., Rosewell I.R., Stamp G.W.H., Beddington R S.P., Mundlos S., Olsen B.R , Selby P.B., Owen M.J.: Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89. 765-771, 1997.
12. Weinstein R.S., Jilka R.L , Parfitt A.M., Manolagas S.C.: The effects of androgen deficiency on murine bone remodeling and bone mineral density are mediated via cells of the osteoblastic lineage. Endocrinology 138: 4013-4021, 1997
13. Manolagas S.C., Jilka R.L.: Mechanisms of disease: Bone marrow, cytokines. and bone remodeling - Emerging insights into the pathophysiology of osteoporosis. N. Engl J. Med 332: 305-311, 1995.
14. Girasole G., Jilka R.L., Passeri G., Boswell S., Boder G., Williams D.C., Manolagas S.C.: 17β-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro. J. Clin. Invest. 89: 883-891, 1992.
15. Pottratz S.T., Bellido T., Mocharla H., Crabb D., Manolagas S.C.: 17β-estradiol inhibits expression of human interleukin-6 promoter-reporter constructs by a receptor-dependent mechanism. J. Clin. Invest. 93: 944-950, 1994.
16. Bellido T., Jilka R.L., Boyce B.F., Girasole G., Broxmeyer H., Dalrymple S.A., Murray R., Manolagas S.C.: Regulation of interleukin-6, osteoclastogenesis and bone mass by androgens: the role of the androgen receptor. J. Clin. Invest. 95: 2886-2895, 1995.
17. Galien R., Evans H.F., Garcia T.: Involvement of ccaat/enhancer-binding protein and nuclear factor-kb binding sites in interleukin-6 promoter inhibition by estrogens. Mol. Endocrinol. 10: 713-722, 1996.
18. Nuttall M.E , Nadeau D., Prichett WP, Gowen M.: Idoxifene, a tissue selective estrogen agonist/antagonist, has a mechanism of action in bone similar to estrogen and distinct from raloxifene. J. Bone Miner. Res. 12 (S1): S170, 1997.
19. McDonnell D P , Norris J.D : Analysis of the molecular pharmacology of estrogen receptor agonists and antagonists provides insights into the mechanism of action of estrogen on bone. Osteoporos. Int. 7 (Suppl. 1)- S29-S34, 1997.
20. Jilka R.L., Hangoc G., Girasole G., Passeri G., Williams D C., Abrams J.S., Boyce B., Broxmeyer H., Manolagas S.C : Increased osteoclast development after estrogen loss: Mediation by interleukin-6. Science 257: 88-91, 1992.
21. Poli V., Balena R., Fattori E., Markatos A., Yamamoto A., Tanaka H., Ciliberto G., Rodan G A., Costantini F.: Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 13: 1189-1196, 1994.
22. Stahl N., Boulton T.G., Farruggella T., Ip N.Y., Davis S., Witthuhn B.A., Quelle F.W., Silvennoinen O., Barbieri G., Pellegrini S., Ihle J-N., Yancopoulos G.D.: Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 β receptor components. Science 263: 92-95, 1994.
23. Narazaki M., Yasukawa K., Saito T., Ohsugi Y., Fukui H., Koishihara Y., Yancopoulos G.D., Taga T., Kishimoto T.: Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 82: 1120-1126, 1993.
24. Udagawa N., Takahashi N., Katagiri T., Tamura T., Wada S., Findlay D.M., Martin T.J., Hirota H., Tada T., Kishimoto T., Suda T.: Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J. Exp. Med. 182: 1461-1468, 1995.
25. Lin S.C., Yamate T., Taguchi Y., Borba V., Girasole G., O'Brien C.A., Bellido T., Abe E., Manolagas S C : Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow. J. Clin. Invest. 100: 1880-1890, 1997.
26. Jilka R.L., Takahashi K., Munshi M., Williams D.C., Roberson P., Manolagas S.C.: Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow: evidence for autonomy from factors released during bone resorption. J. Clin. Invest. 101: 1942-1950, 1998
27. Bellido T., Stahl N., Farruggella T.J., Borba V., Yancopoulos G.D., Manolagas S.C.: Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells. J. Clin. Invest. 97: 431-437, 1996.
28. Bellido T., Borba V.Z.C., Roberson P., Manolagas S.C.: Activation of the JAK/STAT signal transduction pathway by IL-6 type cytokines promotes osteoblast differentiation. Endocrinology 138: 3666-3676, 1997.
29. Taguchi T., Yamate T , Mocharla H., Lin S-C., Vertino A., DeTogni P., Abe E., Manolagas S.C.: Interleukin-6 induces osteoblast differentiation in uncommitted embryonic fibroblasts (EF). Proc. Ass. Am. Phys., 1998 (in press).
30. Metcalf D., Gearing D.P.: Fatal syndrome in mice engrafted with cells producing high levels of the leukemia inhibitory factor. Proc. Natl. Acad. Sci. USA 86: 5948-5952, 1989.
31. Malik N., Haugen H.S., Modrell B., Shoyab M., Clegg C.H.: Developmental abnormalities in mice transgenic for bovine oncostatin M. Mol Cell. Biol 15: 2349-2358, 1995
32. Ware C.B., Horowitz M.C., Renshaw B.R , Hunt J.S., Liggit D., Koblar S.A., Gliniak B.C., McKenna H.J., Papayannopoulou T., Thoma B., Cheng L., Donovan P.J., Peschon J.J., Bartlett P F., Willis C.R., Wright B.D., Carpenter M.K., Davison B.L., Gearling D.P.: Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death. Development 121: 1283-1299, 1995.
33. Jilka R.L., Weinstein R.S., Takahashi K., Parfitt A.M., Manolagas S.C.: Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. J. Clin. Invest. 97: 1732-1740, 1996.
34. 3, on osteoclast-like cell formation in normal human bone marrow cultures., J. Bone Miner. Res. 13: 393-399, 1998.
35. Kimble R.B., Srivastava S., Pacifici R.: Estrogen inhibits macrophage TNF gene expression by modulating binding of transcription factors to the AP-1 binding site. J. Bone Miner. Res. 12(S1): S441, 1997.
36. Sunyer T., Lewis J., Osdoby P.: Estrogen decreases the steady state levels of the IL-1 signaling receptor (Type I) while increasing those of the IL-1 decoy receptor (Type II) mRNAs in human osteoclast-like cells. J. Bone Miner. Res. 12(S1): S135, 1997.
37. Lorenzo J., Naprta A., Rao Y., Alander C., Glaccum M., Gronowicz G., Kalinowski J., Pilbeam C.: Mice deficient in the functional interleukin-1 receptor I (IL-1R1) do not lose bone mass after ovariectomy. J. Bone Miner. Res. 12(S1); S126, 1997.
38. Ammann P., Rizzoli R., Bonjour J.P., Bourrin S.J., Meyer M., Vassalli P., Garcia L: Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J. Clin. Invest 99: 1699-1703, 1997.
39. Kitazawa R., Kimble R.B., Vannice J.L., Rung V.T., Pacifici R., Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice J. Clin. Invest. 94: 2397-2406, 1994.
40. Scharla S.H., Strong D.D., Mohan S., Chevalley T., Linkhart T.A.: Effect of tumor necrosis factor-alpha on the expression of insulin-like growth factor I and insulin-like growth factor binding protein 4 in mouse osteoblasts. Eur. J. Endocrinol. 131: 293-301, 1994.
41. Xie J., Stroumza J., Graves D.T.: IL-1 down-regulates platelet-derived growth factor-receptor gene expression at the transcriptional level in human osteoblastic cells. J. Immunol. 153: 378-385, 1994.
42. Tsukamoto T., Matsui T , Nakata H., Ito M., Natazuka T., Fukase M., Fujita T.: Interleukin-1 enhances the response of osteoblasts to platelet-derived growth factor through the receptor-specific upregulation J. Biol. Chem. 266: 10143-10147, 1991.
43. Wetzler M., Talpaz M., Lowe D.G., Baiocchi G., Gutterman J.U., Kurzrock R.: Constitutive expression of leukemia inhibitory factor RNA by human bone marrow stromal cells and modulation by IL-1, TNF-α, and TGF-β. Exp. Hematol 19: 347-351, 1991.
44. Kimble R.B., Srivastava S., Ross F.P., Matayoshi A., Pacifici R., Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1 and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production. J. Biol. Chem. 271: 28890-28897, 1996.
45. Yamate T., Mocharla H., Taguchi Y., Igietseme J.U., Manolagas S.C , Abe E., Osteopontin expression by osteoclast and osteoblast progenitors in the murine bone marrow: demonstration of its requirement for osteoclastogenesis and its increase after ovariectomy. Endocrinology 138: 3047-3055, 1997.
46. Yang N.N., Bryant H.U., Hardikar S., Sato M., Galvin R.J.S., Glasebrook A L., Termine J.D.: Estrogen and raloxifene stimulate transforming growth factor- 3 gene expression in rat bone: A potential mechanism for estrogen- or raloxifene-mediated bone maintenance. Endocrinology 137: 2075-2084, 1996.
47. Yang N.N., Venugopalan M., Hardikar S., Glasebrook A.: Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 273: 1222-1225, 1996.
48. Yang N.N., Venugopalan M., Hardikar S., Glasebrook A.: Correction: raloxifene response needs more than an element (Letter). Science 275: 1249, 1997.
49. Finkelman R.D., Bell N.H., Strong D.D., Demers L.M., Baylink D.J.: Ovariectomy selectively reduces the concentration of transforming growth factor-β in rat bone: Implications for estrogen deficiency-associated bone loss. Proc. Natl. Acad. Sci. USA 89: 12190-12193, 1992.
50. Cavolina J.M., Evans G.L, Harris S.A., Zhang M., Westerlind K., Turner R.T.: The effects of orbital spaceflight on bone histomorphometry and messenger ribonucleic acid levels for bone matrix proteins and skeletal signaling peptides in ovariectomized growing rats. Endocrinology 138: 1567-1576, 1997.
51. Bonewald. L. Transforming growth Factor-β. In: Bilezikian J.P., Raisz L., Rodan G.A (Eds.), Principles of Bone Biology. Academic Press, San Diego, CA, 1996, pp. 647-659.
52. 1 decrease ovariectomy-stimulated osteoclastic resorption in vivo in rats. J. Bone Miner. Res. 10: 971-977, 1995.
53. Hughes D.E., Dai A., Tiffee J.C., Li H.H., Mundy G.R., Boyce B.F. : Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β. Nature Medicine 2: 1132-1136, 1996.
54. Erlebacher A., Derynck R.: Increased expression of TGF-β 2 in osteoblasts results in an osteoporosis-like phenotype. J. Cell. Biol. 132: 195-210, 1996.
55. Filvaroff E.H., Erlebacher A., Ye J.Q., Gitelman S.E., Lotz J.C., Heilmann M.R., Derynck R.: Increased trabecular bone in transgenic mice expressing a truncated, dominant-negative, type II TGF-β receptor in osteoblasts. J. Bone Miner. Res. 12(S1): S118, 1997.
56. Carani C., Qin K., Simoni M., Faustini-Fustini M., Serpente S., Boyd J., Korach K., Simpson E.: Effect of testosterone and estradiol in a man with aromatase deficiency. NEJM 337: 91-95, 1997.
57. Vanderschueren D., Van Herck E., Nijs J., Ederveen A.G., De Coster R., Bouillon R.: Aromatase inhibition impairs skeletal modeling and decreases bone mineral density in growing male rats. Endocrinology 138: 2301-2307, 1997.
58. Kajkenoua O., Lecka-Czernik B., Gubrij L, Hauser S.P., Takahashi K., Parfitt A.M., Jilka R.L., Manolagas S C., Lipschitz D.A.: Increased adipogenesis and myelopoiesis in the bone marrow of SAMP6, a murine model of defective osteoblastogenesis and low turnover osteopenia. J. Bone Miner. Res. 12: 1772-1779, 1997.
59. Steller H.: Mechanisms and genes of cellular suicide. Science 267: 1445-1449, 1995.
60. Thompson C.B.: Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456-1462, 1995.
61. Lutton J.D., Moonga B.S., Dempster D.W.: Osteoclast demise in the rat: Physiological versus degenerative cell death. Exp. Physiol. 81. 251-260, 1996.
62. Parfitt A.M.: Bone-forming cells in clinical conditions. In: Hall B.K. (Ed.), Bone. Vol. 1. The Osteoblast and Osteocyte. Telford Press and CRC Press, Boca Raton, FL, 1990, pp. 351-429.
63. Jilka R.L., Weinstein R.S., Bellido T., Parfitt A.M., Manolagas S.C.: Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J. Bone Miner. Res. 13: 793-802, 1998.
64. Bellido T., Jilka R.L., Manolagas S.C.: Gp 130/stat3 activation stimulates the transcription of the cyclin dependent kinase inhibitor p21 WAF1,CIP1 gene in osteoblasts: a prerequisite for the biologic effects of IL-6 type cytokines. J. Biol. Chem., 1998 (in press)
65. Jilka R.L., Smith C., Manolagas S.C., Dexamethasone promotes apoptosis of osteoblast progenitors in murine bone marrow cultures: antagonism by IL-6 type cytokines. J. Bone Miner. Res. 12(S1): S455, 1997.
66. Weinstein R.S., Jilka R.L., Parfitt A.M., Manolagas S.C.: Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: Potential mechanisms of their deleterious effects on bone. J. Clin. Invest., 1998 (in press).
67. Aarden E.M , Burger E.H., Nijweide P.J.: Function of osteocytes in bone. J. Cell. Biochem. 55: 287-299, 1994.
68. Tomkinson A., Reeve J., Shaw R.W., Noble B.S., The death of osteocytes via apoptosis accompanies oestrogen withdrawal in human bone. J. Clin. Endocrinol. Metab. 82: 3128-3135, 1997.
69. Frost H-M.: In vivo osteocyte death. J Bone Joint Surg. 42A: 138-143, 1960